Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

DOI Full Paper Access

237

Citations

12

References

2020

Year

Timothy A. Yap, Brent O’Carrigan, Marina S. Penney, Joline S.J. Lim, Jessica Brown, Maria J. de Miguel, Nina Tunariu, Raquel Pérez-López, Daniel Nava Rodrigues, Ruth Riisnaes,

Journal of Clinical Oncology

Abstract

To our knowledge, this report is the first of an ATR inhibitor as monotherapy and combined with carboplatin. M6620 was well tolerated, with target engagement and preliminary antitumor responses observed.

References

	Year	Citations

Page 1